Companies › SHINKEI Therapeutics
1 active drug program in 1 registered trial: 1 Phase 2; Neurology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Amantadine Hydrochloride (MR-301) Glutamate [NMDA] receptor antagonist; Matrix protein 2 inhibitor | GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B | Phase 2 | Traumatic Brain Injury | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06253923 | Amantadine Hydrochloride (MR-301) | Phase 2 | Traumatic Brain Injury | Neurology | Jul 2025 |
Aptinyx Exciva Neuron23 Bial R&D Investments NeuroTherapia
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.